Business
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe
LA JOLLA, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the
About this update from Medicinova, Inc.
[{"type":"text","content":"LA JOLLA, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of alcohol use disorder. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than May 2037. The allowed claims cover a method of treating a patient diagnosed with alcohol use disorder in which the patient also exhibits symptoms of depression with MN-166 (ibudilast). The allowed claims cover a wide range of dosage strengths and dosing regimens of MN-166 (ibudilast). The allowed claims also cover combination therapies of MN-166 (ibudilast) and one or more other therapeutic agents. Kazuko Matsuda, MD, PhD, MPH, Chief Medical Officer of MediciNova, Inc., commented, \"We are very pleased to receive notice that this new patent will be granted. We believe it could substantially increase the potential value of MN-166 as it further strengthens our patent portfolio for drug addiction and drug dependence. We previously reported positive data from two different clinical trials of MN-166 in alcohol use disorder including a 45% reduction (p=0.04) in the odds of heavy drinking and a reduction in alcohol craving (p","length":1733,"tagName":"div"}]